TAP1 and neoplasm: On the other hand, recently, researchers have illustrated that the silent TAP1 induced the presentation of a TAP-independent peptide in human tumor cells, and thereby enhanced the effectiveness of immune potentiating therapies (24, 25), which is additionally considered associated with tumor drug resistance (26–28).